Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
70%(7 trials)

Phase Distribution

Ph phase_1
1
10%
Ph phase_2
3
30%
Ph phase_3
6
60%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
6(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(10)

Detailed Status

Completed10

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 36 (60.0%)

Trials by Status

completed10100%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_3

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830
completedphase_2

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

NCT03959488
completedphase_1

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

NCT04540627
completedphase_3

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

NCT02968173
completedphase_3

"Palivizumab Therapy for RSV-bronchiolitis"

NCT02442427
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04938830Phase 3

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Completed
NCT03959488Phase 2

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Completed
NCT04540627Phase 1

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Completed
NCT02968173Phase 3

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Completed
NCT02442427Phase 3

"Palivizumab Therapy for RSV-bronchiolitis"

Completed
NCT00129766Phase 3

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Completed
NCT01466062Phase 3

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Completed
NCT00538785Phase 2

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Completed
NCT01006629Phase 2

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Completed
NCT00014391Phase 3

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10